Faron Pharmaceuticals Oy (4FR.F)
| Previous Close | 1.5060 |
| Open | 1.4900 |
| Bid | 1.5660 x N/A |
| Ask | 1.6140 x N/A |
| Day's Range | 1.4900 - 1.4900 |
| 52 Week Range | 1.3460 - 4.4500 |
| Volume | |
| Avg. Volume | 56 |
| Market Cap | 107.291M |
| Beta (5Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireFaron Confirms Plans for the Coming Months Under New Leadership
Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activa
- GlobeNewswire
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.While data do not yet allow the precise estimation of median overall survival, the survival benefit seen with the current follow-up already for these 5 first patients is very encouraging. This compares favorably to what has been seen with contempor
News DirectFaron Pharmaceuticals reports promising phase 1 results from BEXMAB study
Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMA...
